| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44041990 | HTLV-1 | ENSG00000183454.19 | protein_coding | GRIN2A | No | Yes | 2903 | Q12879 |
| TVIS44042002 | HTLV-1 | ENSG00000183454.19 | protein_coding | GRIN2A | No | Yes | 2903 | Q12879 |
| TVIS44047432 | HTLV-1 | ENSG00000183454.19 | protein_coding | GRIN2A | No | Yes | 2903 | Q12879 |
| TVIS44042001 | HTLV-1 | ENSG00000183454.19 | protein_coding | GRIN2A | No | Yes | 2903 | Q12879 |
| TVIS44042000 | HTLV-1 | ENSG00000183454.19 | protein_coding | GRIN2A | No | Yes | 2903 | Q12879 |
| TVIS44041985 | HTLV-1 | ENSG00000183454.19 | protein_coding | GRIN2A | No | Yes | 2903 | Q12879 |
| TVIS44041929 | HTLV-1 | ENSG00000183454.19 | protein_coding | GRIN2A | No | Yes | 2903 | Q12879 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | GRIN2A |
|---|---|
| DrugBank ID | DB00142 |
| Drug Name | Glutamic acid |
| Target ID | BE0000760 |
| UniProt ID | Q12879 |
| Regulation Type | |
| PubMed IDs | 17139284; 17016423; 12068077; 11080203; 8886398 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Rutter AR, Freeman FM, Stephenson FA: Further characterization of the molecular interaction between PSD-95 and NMDA receptors: the effect of the NR1 splice variant and evidence for modulation of channel gating. J Neurochem. 2002 Jun;81(6):1298-307.@@Rutter AR, Stephenson FA: Coexpression of postsynaptic density-95 protein with NMDA receptors results in enhanced receptor expression together with a decreased sensitivity to L-glutamate. J Neurochem. 2000 Dec;75(6):2501-10.@@Bresink I, Benke TA, Collett VJ, Seal AJ, Parsons CG, Henley JM, Collingridge GL: Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. Br J Pharmacol. 1996 Sep;119(2):195-204. |
| Groups | Approved; Nutraceutical |
| Direct Classification | Glutamic acid and derivatives |
| SMILES | N[C@@H](CCC(O)=O)C(O)=O |
| Pathways | Histidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); 3-Methylglutaconic Aciduria Type I; beta-Ketothiolase Deficiency; Purine Nucleoside Phosphorylase Deficiency; Tyrosine Metabolism; Ketoprofen Action Pathway; Glutamate Metabolism; Argininosuccinic Aciduria; Salla Disease/Infantile Sialic Acid Storage Disease; Tyrosinemia Type I; Hyperinsulinism-Hyperammonemia Syndrome; 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency; Glutaric Aciduria Type I; Propanoate Metabolism; Celecoxib Action Pathway; Glycine and Serine Metabolism; Suprofen Action Pathway; Indomethacin Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Sialuria or French Type Sialuria; Ibuprofen Action Pathway; Saccharopinuria/Hyperlysinemia II; Histidine Metabolism; Arginine and Proline Metabolism; Purine Metabolism; Diflunisal Action Pathway; Etodolac Action Pathway; Ammonia Recycling |
| PharmGKB | PA449776 |
| ChEMBL | CHEMBL575060 |
